Table 1.
Comorbidities according to Charlson adapted for patients with ESRD and additional concomitant diseases (n = 860)
| Chronic Itch (all prevalence estimates) | Total | ||
|---|---|---|---|
| Yes, % (n) | No, % (n) | (n = 860) | |
| (n = 307) | (n = 553) | ||
| Comorbidities (according to Charlson) | Relative frequency, % (n) | Relative frequency, % (n) | Relative frequency, % (n) |
| Myocardial infarction | 16.6 (51) | 16.8 (93) | 16.7 (144) |
| Congestive heart failure | 22.8 (70) | 25.7 (142) | 24.7 (212) |
| Peripheral vascular disease | 20.0 (62) | 21.7 (120) | 21.2 (182) |
| Cerebral vascular disease | 12.7 (39) | 15.7 (87) | 14.7 (126) |
| Dementia | 1.6 (5) | 1.8 (10) | 1.7 (15) |
| Chronic lung disease | 20.8 (64) | 18.6 (103) | 19.4 (167) |
| Rheumatological disease | 2.9 (9) | 2.9 (16) | 2.9 (25) |
| Peptic ulcer disease | 7.8 (24) | 8.5 (47) | 8.3 (71) |
| Hemiplegia | 1.3 (4) | 2.5 (14) | 2.1 (18) |
| Diabetes without complications | 30.9 (95)* | 42.0 (232)** | 38.0 (327) |
| Diabetes with complications | 22.8 (70)* | 31.8 (167)** | 28.6 (246) |
| Mild liver disease | 5.2 (16) | 4.3 (24) | 4.7 (40) |
| Moderate/severe liver disease | 2.0 (6) | 1.4 (8) | 1.6 (14) |
| Metastatic disease | 13.0 (40) | 12.1 (67) | 12.4 (107) |
| Leukemia | 0.3 (1) | 0.2 (1) | 0.2 (2) |
| Lymphoma | 3.9 (12) | 3.1 (17) | 3.4 (29) |
| Human immunodeficiency virus | - | - | - |
| Charlson Comorbidity Index, mean ± SD | 4.1 ± 4.4 | 4.4 ± 4.6 | 4.3 ± 4.5 |
| Charlson score 0 | 25.7 (79) | 23.3 (129) | 24.2 (208) |
| Charlson score 1–2 | 18.9 (58) | 17.5 (97) | 18.0 (155) |
| Charlson score 3–4 | 19.5 (60) | 20.6 (114) | 20.0 (174) |
| Charlson score ≥5 | 35.8 (110) | 38.5 (213) | 37.6 (323) |
| Additionally assessed comorbidities | |||
| Arterial hypertension | 87.6 (269) | 87.5 (484) | 87.6 (753) |
| Anemia | 95.1 (292) | 92.9 (514) | 93.7 (806) |
| Hyperparathyroidism | 85.0 (261) | 83.2 (460) | 83.8 (721) |
| Dyslipidemia | 39.7 (122) | 41.4 (229) | 40.8 (351) |
| Osteoporosis | 6.2 (19) | 5.1 (28) | 5.5 (47) |
*Significantly lower than average at p < 0.05
**Significantly higher than average at p < 0.05